Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CECR2 | Q9BXF3 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | TAF1 | P21675 | 2/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | TAF11 | Q15544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657115 | 0.84 | BRD4 (0.50) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL19651854 | 0.84 | HSP90AA1 (0.46) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL19657106 | 0.80 | HPGD (0.48) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL19657124 | 0.80 | BRD4 (0.47) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL19657112 | 0.74 | HTT (0.47) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL19651863 | 0.74 | HSP90AA1 (0.54) | CECR2BRD4TAF1BRD9HPGD | |
| SCHEMBL4791767 | 0.71 | CNR1 (0.47) | BRD9HTTHPGDTSHRMAPT | |
| SCHEMBL19657218 | 0.71 | MAPT (0.59) | HTTHPGDTSHRMAPTKDM4E | |
| SCHEMBL19651852 | 0.69 | BRD4 (0.48) | CECR2BRD4TAF1BRD9HTT | |
| SCHEMBL12813152 | 0.69 | KMT2A (0.58) | HTTHPGDTSHRKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | CECR2 246/4885BRD4 1/4885TAF1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.